Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| [18F] | Fluorine-18 (radiolabel of fluorodeoxyglucose) |
| 1L, 2L, 3L, 4L | First-, second-, third-, and fourth-line therapy |
| 2/3L, 2L/3L+ | Second- or third-line therapy; second-line or third-or-later-line therapy |
| 4OH-tamoxifen | 4-Hydroxytamoxifen |
| AAC | Actual acquisition cost |
| ABC, aBC | Advanced breast cancer |
| ABC8 | 8th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer |
| ADC, ADCs | Antibody-drug conjugate |
| ADLT | Advanced Diagnostic Laboratory Test |
| ADP | Adenosine diphosphate (in poly [ADP-ribose] polymerase) |
| AE, AEs | Adverse event |
| AF, AF-1, AF-2, AF1, AF2 | Activation function; activation function 1 (N-terminal, ligand-independent) and 2 (C-terminal, ligand-dependent) domains of the estrogen receptor |
| AHFS | American Hospital Formulary Service |
| AI, AIs | Aromatase inhibitor |
| AKT, AKT1, AKT2, AKT3 | AKT serine/threonine kinase (protein kinase B) and its isoforms 1, 2, and 3 |
| AKT1mut | AKT1 mutation |
| ALT | Alanine aminotransferase |
| A/MBC | Advanced or metastatic breast cancer |
| AP | Alkaline phosphatase (estrogenic agonist activity assay) |
| aRR | Adjusted risk ratio |
| ASCO | American Society of Clinical Oncology |
| ASCO/CAP, ASCO-CAP | American Society of Clinical Oncology and College of American Pathologists |
| AST | Aspartate aminotransferase |
| ASTRO | American Society for Radiation Oncology |
| ATC | Anatomical Therapeutic Chemical classification |
| AUC | Area under the concentration-time curve |
| AUC0–24, AUC0-24, AUC0–24,ss | Area under the concentration-time curve from time 0 to 24 hours (at steady state) |
| AWP | Average wholesale price |
| BC | Breast cancer |
| BCRP | Breast cancer resistance protein |
| BCSS | Breast cancer-specific survival |
| BIA | Budget impact analysis |
| BICR | Blinded independent central review |
| BID | Twice daily |
| BIRC | Blinded independent review committee |
| BL | Basal-like (intrinsic subtype) |
| BM | Brain metastases |
| BMAs | Bone-modifying agents |
| BP | Bone pain |
| BRCA, BRCA1, BRCA2, BRCA1/2 | Breast cancer susceptibility gene (1 and 2) |
| BRCAm, gBRCAm | BRCA-mutated; germline BRCA-mutated |
| C1, C1D1, C1D2, C1D15, C2D15, C3D1, C3D15, C5D1, C7D1, C9D1, D8, D15, D16 | Treatment cycle (C) and day (D); for example, C1D1 is cycle 1, day 1 |
| CADTH | Canadian Agency for Drugs and Technologies in Health |
| CAMA-1 | Estrogen receptor-positive, ESR1 wild-type human breast cancer cell line |
| Cavg, Cavg,ss | Average plasma concentration (at steady state) |
| CBR | Clinical benefit rate |
| CBRAS | Clinical benefit rate analysis set |
| CDK | Cyclin-dependent kinase |
| CDK4, CDK4/6 | Cyclin-dependent kinase 4; cyclin-dependent kinases 4 and 6 |
| CDK4/6i, CDK4/6is | Cyclin-dependent kinase 4 and 6 inhibitor |
| CDx | Companion diagnostic |
| CEHRT | Certified electronic health record technology |
| CERAN, CERANs | Complete estrogen receptor antagonist |
| cfDNA | Cell-free deoxyribonucleic acid |
| CFR | Code of Federal Regulations |
| CGP | Comprehensive genomic profiling |
| ChT | Chemotherapy |
| CI, CIs | Confidence interval |
| CLIA | Clinical Laboratory Improvement Amendments |
| Cmax, Cmax,ss | Maximum plasma concentration (at steady state) |
| Cmin, Cmin,ss | Minimum plasma concentration (at steady state) |
| CMOs | Contract manufacturing organizations |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| CoA | Coactivator |
| cPR, cPRs | Confirmed partial response |
| CQI | Continuous quality improvement |
| CQOLC | Caregiver Quality of Life Index-Cancer |
| CR | Complete response; credible range (cost model output) |
| CRBN | Cereblon |
| CSF | Cerebrospinal fluid |
| CT | Computed tomography |
| CTCs | Circulating tumor cells |
| ctDNA | Circulating tumor deoxyribonucleic acid |
| Ctrough | Trough plasma concentration |
| CY | Calendar year |
| CYP | Cytochrome P450 |
| CYP3A, CYP3A4, CYP3 A4 | Cytochrome P450 subfamily 3A; cytochrome P450 isoenzyme 3A4 |
| Dato-DXd | Datopotamab deruxtecan |
| DC50 | Concentration producing 50% of maximal degradation |
| DCIS | Ductal carcinoma in situ |
| ddPCR | Droplet digital polymerase chain reaction |
| DFI | Disease-free interval |
| DLT, DLTs | Dose-limiting toxicity |
| DNA | Deoxyribonucleic acid |
| dnMBC | De novo metastatic breast cancer |
| DOR, DoR | Duration of response |
| DPYD | Dihydropyrimidine dehydrogenase gene |
| DSP | Disease Specific Programme (Adelphi Real World survey) |
| DVT | Deep vein thrombosis |
| E2 | Estradiol |
| E2F | E2F transcription factor |
| E3 | E3 ubiquitin ligase |
| EAG | External Assessment Group (NICE) |
| EBC | Early breast cancer |
| ECG, ECGs | Electrocardiogram |
| ECOG | Eastern Cooperative Oncology Group |
| ED | Emergency department |
| EFS | Efficacy analysis set |
| EGFR | Epidermal growth factor receptor |
| EHR | Electronic health record |
| ELA | Elacestrant |
| EMA | European Medicines Agency |
| Emax | Maximal effect (maximal degradation or inhibition) |
| EOL | End of life |
| EOM | Enhancing Oncology Model |
| EORTC | European Organisation for Research and Treatment of Cancer |
| ePROs | Electronic patient-reported outcomes |
| EQ-5D-3L, EQ-5D-5L, EQ-5D-5 L | EuroQol 5-dimension health status instrument (3-level and 5-level versions) |
| ER | Estrogen receptor |
| ER+ | Estrogen receptor-positive |
| ERα, ERa, ERalpha | Estrogen receptor alpha |
| ERBB2 | Erb-b2 receptor tyrosine kinase 2 (gene encoding HER2) |
| ERK | Extracellular signal-regulated kinase |
| ESCAT | ESMO Scale for Clinical Actionability of molecular Targets |
| ESMO | European Society for Medical Oncology |
| ESMO-MCBS | ESMO Magnitude of Clinical Benefit Scale |
| ESR1, ESR-1 | Estrogen receptor 1 gene |
| ESR1m, ESR1mut, ESR1-mut, ESR1-MUT, mutESR1 | ESR1 mutation or ESR1-mutated |
| ESR1-mut-nd | ESR1 mutation not detected |
| ESR1-wt, ESR1-WT | ESR1 wild-type |
| ET, ETs | Endocrine therapy |
| E.U., EU | European Union |
| EVE | Everolimus |
| evLYG | Equal value of life-years gained |
| EXE | Exemestane |
| FA | Final analysis |
| FACT-B | Functional Assessment of Cancer Therapy-Breast |
| FAS | Full analysis set |
| FAT1 | FAT atypical cadherin 1 gene |
| FDA | Food and Drug Administration |
| FG | Fasting glucose |
| FGFR1 | Fibroblast growth factor receptor 1 |
| FHRD | Flatiron Health Research Database |
| FPG | Fasting plasma glucose |
| FT | Financial toxicity |
| FUL | Fulvestrant |
| GA | Genomic alteration |
| GeoCV | Geometric coefficient of variation |
| GeoMean | Geometric mean |
| GHS | Global health status |
| GHS/QoL, GHS/QOL | Global health status/quality of life (EORTC QLQ-C30 scale) |
| GLOBOCAN | Global Cancer Observatory estimates of cancer incidence, mortality, and prevalence (International Agency for Research on Cancer) |
| GnRH | Gonadotropin-releasing hormone |
| GREB1 | Growth regulating estrogen receptor binding 1 gene |
| H12 | Helix 12 of the estrogen receptor ligand-binding domain |
| HDI | Human Development Index |
| HER2, HER-2 | Human epidermal growth factor receptor 2 |
| HER2+ | Human epidermal growth factor receptor 2-positive |
| HER2/neu | Human epidermal growth factor receptor 2 (neu oncogene product) |
| hERG | Human ether-a-go-go-related gene (potassium channel) |
| HHNKS | Hyperglycemic hyperosmolar nonketotic syndrome |
| HICs | High-income countries |
| HR, HRs | Hazard ratio; hormone receptor; heart rate |
| HR+, HR- | Hormone receptor-positive, hormone receptor-negative |
| HRQoL, HRQOL | Health-related quality of life |
| HRSN | Health-related social needs |
| HTA | Health technology assessment |
| IC50 | 50% inhibitory concentration |
| ICC | Investigator's choice of chemotherapy |
| ICER, ICERs | Incremental cost-effectiveness ratio |
| ICH | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use |
| ICH E14 | ICH guideline E14 on clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential |
| ICUR | Incremental cost-utility ratio |
| ID | Identifier |
| IDMC | Independent data monitoring committee |
| IHC | Immunohistochemistry |
| ILD | Interstitial lung disease |
| IM | Intramuscular |
| INN | International nonproprietary name |
| IOM | Institute of Medicine |
| IP | Inpatient |
| IQR | Interquartile range |
| IS | Intrinsic subtype |
| ISH | In situ hybridization |
| ITC | Indirect treatment comparison |
| ITT | Intent to treat |
| JPY | Japanese yen |
| Ki67 | Ki-67 nuclear proliferation antigen |
| KM | Kaplan-Meier |
| LABC | Locally advanced breast cancer |
| LBD | Ligand-binding domain |
| LBx | Liquid biopsy |
| LHRH | Luteinizing hormone-releasing hormone |
| LMD | Leptomeningeal disease |
| LMICs | Low- and middle-income countries |
| M1 | Distant metastasis category of the TNM staging system |
| MAEs | Major adverse events |
| MAIC | Matching-adjusted indirect comparison |
| MAPK | Mitogen-activated protein kinase |
| MBC, mBC | Metastatic breast cancer |
| MCF7 | Estrogen receptor-positive, ESR1 wild-type human breast cancer cell line (Michigan Cancer Foundation-7) |
| mCRC | Metastatic colorectal cancer |
| MD | Maryland |
| MEK | Mitogen-activated protein kinase kinase |
| MG-132 | Peptide aldehyde proteasome inhibitor (research compound) |
| MIPS | Merit-based Incentive Payment System |
| mLC | Metastatic lung cancer |
| mOS | Median overall survival |
| mPFS | Median progression-free survival |
| MRI | Magnetic resonance imaging |
| MTD | Maximum tolerated dose |
| mTOR | Mechanistic target of rapamycin |
| mTORC1, mTORC2 | Mechanistic target of rapamycin complex 1 and complex 2 |
| mTORi | Mechanistic target of rapamycin inhibitor |
| mTTNT | Median time to next treatment |
| NA | Not available (table values) |
| NCCN | National Comprehensive Cancer Network |
| NCI | National Cancer Institute |
| NCI-CTCAE | National Cancer Institute Common Terminology Criteria for Adverse Events |
| NCoR, NCoR1 | Nuclear receptor corepressor (1) |
| NCT | National Clinical Trial (ClinicalTrials.gov identifier) |
| NDA, NDAs | New Drug Application |
| NDC | National Drug Code |
| NE | Not estimable |
| NEOL | Non-end of life |
| NGS | Next-generation sequencing |
| NHS | National Health Service (England) |
| NICE | National Institute for Health and Care Excellence |
| NR3A1 | Nuclear receptor subfamily 3, group A, member 1 (estrogen receptor alpha) |
| OCM | Oncology Care Model |
| ONS | Oncology Nursing Society |
| OP | Outpatient |
| OP-1250 | Olema Oncology development code for palazestrant |
| OP-3136 | Olema Oncology development code for an investigational lysine acetyltransferase 6 (KAT6) inhibitor |
| ORR | Objective response rate; overall response rate |
| OS | Overall survival |
| OWSA | One-way sensitivity analysis |
| PALB2 | Partner and localizer of BRCA2 gene |
| PARP | Poly(adenosine diphosphate-ribose) polymerase |
| PARPi | Poly(adenosine diphosphate-ribose) polymerase inhibitor |
| PBO | Placebo |
| PCR | Polymerase chain reaction |
| PD | Pharmacodynamic |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PET | Positron emission tomography |
| PF | Pathological fracture |
| PFS | Progression-free survival |
| PFS2 | Progression-free survival on the next line of therapy |
| P-gp | P-glycoprotein |
| PGR, PgR | Progesterone receptor (gene) |
| PI3K | Phosphatidylinositol 3-kinase |
| PI3Kα, PI3Ka, PI3K-alpha | Phosphatidylinositol 3-kinase alpha |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene |
| PIK3CAmut | PIK3CA mutation |
| PK | Pharmacokinetics |
| PO | Orally |
| PPP6 M | Per patient per 6 months |
| PPPM | Per patient per month |
| PR, PRs | Partial response |
| PRAs | Participant redesign activities (Enhancing Oncology Model) |
| PRO, PROs | Patient-reported outcome |
| PROTAC | Proteolysis targeting chimera |
| PSA | Probabilistic sensitivity analysis |
| PSM | Partitioned survival model |
| PTE | Patent term extension |
| PTEN | Phosphatase and tensin homolog gene |
| Q3, Q4 | Third and fourth quarter of the year |
| QALY, QALYs | Quality-adjusted life year |
| QD | Once daily |
| QLQ-BR23 | EORTC Quality of Life Questionnaire breast cancer module (23 items) |
| QLQ-C30 | EORTC Quality of Life Questionnaire Core 30 |
| QoL | Quality of life |
| QT | QT interval |
| QTc | QT interval corrected for heart rate |
| QTcF | QT interval corrected using the Fridericia method |
| R2PD, RP2D | Recommended phase 2 dose |
| RAF | Rapidly accelerated fibrosarcoma kinase |
| RANK | Receptor activator of nuclear factor kappa B |
| RAS | Rat sarcoma GTPase |
| RB, RB1 | Retinoblastoma protein; retinoblastoma 1 gene |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| REMS | Risk Evaluation and Mitigation Strategy |
| rMBC | Recurrent metastatic breast cancer |
| RR | Relative risk (rate ratio) |
| RT | Radiation therapy |
| RTKs | Receptor tyrosine kinases |
| rwOS | Real-world overall survival |
| rwPFS, rwPFS-2L, rwPFS-3L | Real-world progression-free survival (in second-line and third-line therapy) |
| SABCS | San Antonio Breast Cancer Symposium |
| SAE, SAEs | Serious adverse event |
| SAF | Safety analysis set |
| SCC | Spinal cord compression |
| SD | Stable disease; standard deviation |
| SE | Standard error |
| SEER | Surveillance, Epidemiology, and End Results program |
| SERCAs | Selective estrogen receptor covalent antagonists |
| SERD, SERDs | Selective estrogen receptor degrader |
| SERM, SERMs | Selective estrogen receptor modulator |
| SG | Sacituzumab govitecan |
| sIPTW | Stabilized inverse probability of treatment weighting |
| SNVs | Single nucleotide variants |
| SOC | Standard of care |
| SRE, SREs | Skeletal-related event |
| ss | Steady state (subscript in pharmacokinetic parameters) |
| SSO | Society of Surgical Oncology |
| ST941C | ESR1-mutant breast cancer cell line derived from the ST941 patient-derived xenograft model |
| T1, T2 | Primary tumor size categories 1 and 2 of the TNM staging system |
| t1/2, T1/2 | Elimination half-life |
| t1/2eff | Effective half-life |
| T1N0, T1N1–3, T1N4–9, T2N0, T2N1–3, T2N4–9 | Primary tumor category 1 or 2 with no, 1 to 3, or 4 to 9 involved axillary lymph nodes |
| TB01 | TROPION-Breast01 trial |
| TBx | Tissue biopsy |
| T-DXd | Trastuzumab deruxtecan |
| TEAE, TEAEs | Treatment-emergent adverse event |
| TF | Tumor fraction (of circulating cell-free DNA) |
| TIH | Tumor-induced hypercalcemia |
| Tmax, tmax, Tmax,ss | Time to maximum plasma concentration (at steady state) |
| TNBC | Triple-negative breast cancer |
| TPC | Treatment of physician's choice |
| TRAE, TRAEs | Treatment-related adverse event |
| Trop-2 | Trophoblast cell-surface antigen 2 |
| TTD | Time to deterioration |
| TTNT | Time to next treatment |
| TTO | Time trade-off |
| TTP | Time to progression |
| UK | United Kingdom |
| ULN | Upper limit of normal |
| uPR, uPRs | Unconfirmed partial response |
| US, U.S., USA | United States |
| UWW | Uterine wet weight |
| VC | Visceral crisis |
| VMS | Vasomotor symptoms |
| WAC | Wholesale acquisition cost |
| WBC | White blood cell (count) |
| WHO | World Health Organization |
| WP | Work productivity |
| WT | Wild-type |
| WTP | Willingness to pay |